Relevance of quantitative HBsAg (qHBsAg) during long-term treatment of chronic hepatitis B with nucleos(t)ide analogues (NUCs)
J Jaroszewicz, H Ho, K Deterding, A Markova, K Wursthorn, HL Tillmann, S Schulz, TC Bock, MP Manns, H Wedemeyer, M Cornberg · Zeitschrift für Gastroenterologie · 2011 · Heft 01
Bibliografische Angaben
Zusammenfassung
qHBsAg has been show to predict response to interferon alfa but may also be useful to dissect the phase of HBV-infection. The aim of this study was to analyze if qHBsAg is useful for the prediction of HBsAg loss during NUC therapy. HBsAg was quantified in 126 patients with chronic HBV-infection. 95 patients received therapy with NUCs and were followed for 6–107 months. 31 patients not receiving therapy were observed for 36–48 months. We further analyzed serum cytokines by CBA to find additional markers for HBsAg loss. Six patients on NUCs achieved HBsAg loss. Patients with HBsAg loss had higher baseline ALT and…
